Unregistered Sales of Equity Securities and Use of Proceeds.
−Removed: In March 19, 2024, we entered
−Removed: into an At-The-Market Issuance Sales Agreement, as may be amended from time to time (the “Sales Agreement”) with Ascendiant
−Removed: Capital Markets, LLC (“Ascendiant”) under which we may, from time to time, issue and sell shares of our Common Stock having
−Removed: aggregate sales proceeds of up to $22 million, in a series of one or more “at-the-market” equity offerings (the “ATM
−Removed: Ascendiant is not required to sell any specific share amounts but acts as our sales agent, using commercially reasonable
−Removed: efforts consistent with its normal trading and sales practices.
−Removed: We agreed to pay Ascendiant a commission equal to 3.0% of the aggregate
−Removed: gross proceeds we receive from each sale of shares of our Common Stock.
−Removed: Pursuant to the Sales Agreement, any shares will be sold pursuant
−Removed: to our shelf registration statement on Form S-3 (File No.
−Removed: 333-275282) filed with the SEC on November 2, 2023, including the base prospectus
−Removed: contained therein, as declared effective by the SEC on November 29, 2023.
−Removed: Shares of our Common Stock will be sold at prevailing market
−Removed: prices at the time of the sale, and as a result, prices may vary.
−Removed: the period April 1, 2024, through May 13, 2024, the Company has sold 14,352,186 shares of its Common Stock for net proceeds of $20,610.
+Added: On March 19, 2024, we entered into an At-The-Market Issuance Sales
+Added: Agreement, as may be amended from time to time (the “Sales Agreement”) with Ascendiant Capital Markets, LLC (“Ascendiant”)
+Added: under which we may, from time to time, issue and sell shares of our Common Stock having aggregate sales proceeds of up to $30 million,
+Added: in a series of one or more “at-the-market” equity offerings (the “ATM Program”).
+Added: Ascendiant is not required to
+Added: sell any specific share amounts but acts as our sales agent, using commercially reasonable efforts consistent with its normal trading
+Added: and sales practices.
+Added: We agreed to pay Ascendiant a commission equal to 3.0% of the aggregate gross proceeds we receive from each sale
+Added: of shares of our Common Stock.
+Added: Pursuant to the Sales Agreement, any shares will be sold pursuant to our shelf registration statement on
+Added: Form S-3 (File No.
+Added: 333-275282) filed with the SEC on November 2, 2023, including the base prospectus contained therein, as declared effective
+Added: by the SEC on November 29, 2023.
+Added: Shares of our Common Stock will be sold at prevailing market prices at the time of the sale, and as a
+Added: result, prices may vary.
+Added: the period April 1, 2024, through August 5, 2024, the Company has sold 7,340,312 shares of its Common Stock for net proceeds of $1,404.
Defaults Upon Senior Securities.
−Removed: For a discussion of the “ Convertible Promissory Note Due to
−Removed: Novartis ” refer to Note 5 to the Condensed Consolidated Financial Statements (Unaudited) in Part I, Item 1 of this Quarterly
+Added: a discussion of the “ Convertible Promissory Note Due to Novartis ” refer to Note 5 to the Condensed Consolidated Financial
+Added: Statements (Unaudited) in Part I, Item 1 of this Quarterly Report.
Mine Safety Disclosures.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.